About: A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic
Creator	Ooi, Eng-Eong Lau, Yuk-Fai Tang, Lay-Hoon
Source	Elsevier; Medline; PMC
abstract	Abstract The appearance and spread of the H5N1 highly pathogenic avian influenza (HPAI) raise concern of a possible pandemic. Current preventive measures include the development of a pre-pandemic influenza vaccine and stockpiling of neuraminidase inhibitors. However, their benefits can be significantly reduced by mutations in the hemagglutinin or neuraminidase resulting in antigenic changes and the appearance of drug-resistance, respectively. Drugs that target the innate immune system to achieve a ‘heightened antiviral’ state represent another class of antiviral agents that could contribute to the control and treatment of influenza infection. In this study, PIKA (a stabilized dsRNA) provides broad-spectrum prophylaxis against a number of influenza A viruses. In addition, when PIKA was admixed with influenza vaccine preparations, including a formalin-inactivated whole-virion H5 vaccine, significant adjuvanting effect leading to accelerated viral clearance was observed in a murine model. These biological effects appear to be mediated by the ability of PIKA to promote the maturation of dendritic cells, including up-regulation of co-stimulatory molecules, such as CD80 and CD86, and the induction of various cytokines and chemokines. Toll-like receptor 3 (TLR3) was shown to recognize PIKA in a concentration-dependent manner. The potency and versatility in its activities make PIKA an attractive candidate for use in an influenza pandemic.
has issue date	2009-02-25(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2008.12.048
bibo:pmid	19150474
has license	els-covid
sha1sum (hex)	9218063b7a9a4907d674b3284e9eb53a4b9b4d56
schema:url	https://doi.org/10.1016/j.vaccine.2008.12.048
resource representing a document's title	A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic
has PubMed Central identifier	PMC7115584
has PubMed identifier	19150474
schema:publication	Vaccine
resource representing a document's body	covid:9218063b7a9a4907d674b3284e9eb53a4b9b4d56#body_text
is schema:about of	named entity 'ACTIVITY' named entity 'induction' named entity 'ability' named entity 'potent' named entity 'POTENTIAL' named entity 'STUDY' named entity 'SPREAD' named entity 'STABILIZED' named entity 'CONTROL' named entity 'PANDEMIC' named entity 'NEURAMINIDASE' named entity 'CD80' named entity 'INDUCTION' named entity 'H5N1' named entity 'ATTRACTIVE' named entity 'ADDITION' named entity 'PIKA' named entity 'CLASS' named entity 'SIGNIFICANT' named entity 'TARGET' named entity 'CURRENT' named entity 'PROPHYLAXIS' named entity 'THEIR' named entity 'USE' named entity 'RECOGNIZE' named entity 'INFLUENZA VIRUS' named entity 'TLR3' named entity 'INHIBITION' named entity 'LEADING' named entity 'CHANGES' named entity 'INFLUENZA PANDEMIC' named entity 'STATE' named entity 'HEMAGGLUTININ' named entity 'REDUCED' named entity 'CYTOKINES' named entity 'VIRUS REPLICATION' named entity 'DUAL' named entity 'APPLICATIONS' named entity 'INFLUENZA PANDEMIC' named entity 'ADJUVANT' named entity 'STRONG' named entity 'EXHIBITS' named entity 'LIGAND' named entity 'DSRNA' named entity 'INACTIVATED' named entity 'PROVIDES' named entity 'MAKE' named entity 'DENDRITIC CELLS' named entity 'TREATMENT' named entity 'MEDIATED' named entity 'CANDIDATE' named entity 'PREVENTIVE' named entity 'PRE' named entity 'ABILITY' named entity 'VIRAL CLEARANCE' named entity 'INCLUDING' named entity 'ITS' named entity 'THESE' named entity 'PROMOTE' named entity 'UP-REGULATION' named entity 'INNATE IMMUNE SYSTEM' named entity 'INFLUENZA INFECTION' named entity 'BIOLOGICAL' named entity 'DEPENDENT' named entity 'MODEL' named entity 'INFLUENZA A' named entity 'APPEARANCE' named entity 'POSSIBLE' named entity 'VACCINE' named entity 'BROAD' named entity 'REPRESENT' named entity 'HIGHLY PATHOGENIC AVIAN INFLUENZA' named entity 'CONCERN' named entity '28A' named entity 'OBSERVED' named entity 'VIRION' named entity 'ACCELERATED' named entity 'MURINE' named entity 'NUMBER OF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software